The potential of steroids and xenobiotic receptor polymorphisms in forecasting cyclosporine pharmacokinetic variability in young kidney transplant recipients

Pediatric Transplantation

Volumn 16, Issue 6, 2012, Pages 658-663

  Ferraresso, Mariano ^a   Turolo, Stefano ^b   Belinghieri, Mirco ^b   Tirelli, Amedea Silvia ^b   Grillo, Paolo ^b   Groppali, Elena ^b   Edefonti, Alberto ^b   Ghio, Luciana ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

cyclosporine; NR1I2; pediatric kidney transplantation; pharmacogenetics; pharmacokinetics; steroids and xenobiotic receptor

Indexed keywords

CELL NUCLEUS RECEPTOR; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ADOLESCENT; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG METABOLISM; FEMALE; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE;

ADOLESCENT; ADULT; ALLELES; CYCLOSPORINE; FEMALE; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, STEROID; RENAL INSUFFICIENCY; STEROIDS; TIME FACTORS; XENOBIOTICS;

EID: 84864620734     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2012.01751.x     Document Type: Article

References (33)

1. McMillan MA,. Clinical pharmacokinetics of cyclosporin. Pharmacol Ther 1989: 42: 135-156. (Pubitemid 19099824)
2. Akhlaghi F, Trull AK,. Distribution of cyclosporin in organ transplant recipients. Clin Pharmacokinet 2002: 41: 615-637.
3. Wasan KM, Pritchard PH, Ramaswamy M, Wong W, Donnachie EM, Brunner LJ,. Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine. Pharm Res 1997: 14: 1613-1620. (Pubitemid 28009215)
4. Ducharme MP, Warbasse LH, Edwards DJ,. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995: 57: 485-491.
5. Benet LZ,. The drug transporter-metabolism alliance: Uncovering and defining the interplay. Mol Pharm 2009: 6: 1631-1643.
6. Hesselink DA, Van Gelder T, Van Schaik RH, et al., Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004: 76: 545-556. (Pubitemid 39601545)
7. Anglicheau D, Thervet E, Etienne I, et al., CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004: 75: 422-433. (Pubitemid 38534563)
8. Von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW,. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001: 47: 1048-1052. (Pubitemid 32493590)
9. Bouamar R, Hesselink DA, Van Schaik RH, et al., Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation. Ther Drug Monit 2011: 33: 178-184.
10. Pascussi JM, Drocourt L, Fabre JM, Maurel P, Vilarem MJ,. Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: Synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 2000: 58: 361-372. (Pubitemid 30497480)
11. Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ,. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 2001: 268: 6346-6358.
12. Zhang J, Kuehl P, Green ED, et al., The human pregnane X receptor: Genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 2001: 11: 555-572. (Pubitemid 32953582)
13. Lamba J, Lamba V, Schuetz E,. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 2005: 6: 369-383. (Pubitemid 41086769)
14. Turolo S, Tirelli AS, Ferraresso M, et al., Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep 2010: 62: 1159-1169.
15. Zeger SL, Liang KY,. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986: 42: 121-130.
16. Urquhart BL, Tirona RG, Kim RB,. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: Implications for interindividual variability in response to drugs. J Clin Pharmacol 2007: 47: 566-578. (Pubitemid 46632158)
17. Bertilsson G, Heidrich J, Svensson K, et al., Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 1998: 95: 12208-12213. (Pubitemid 28483744)
18. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA,. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998: 102: 1016-1023. (Pubitemid 28419246)
19. Geick A, Eichelbaum M, Burk O,. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001: 276: 14581-14587.
20. Kast HR, Goodwin B, Tarr PT, et al., Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 2002: 277: 2908-2915. (Pubitemid 34953324)
21. Lamba J, Strom S, Venkataramanan R, et al., MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther 2006: 79: 325-338.
22. Lamba J, Lamba V, Strom S, Venkataramanan R, Schuetz E,. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 2008: 36: 169-181.
23. Liu Y, Ji W, Yin Y, et al., The effects of splicing variant of PXR PAR-2 on CYP3A4 and MDR1 mRNA expressions. Clin Chim Acta 2009: 403: 142-144.
24. Dring MM, Goulding CA, Trimble VI, et al., The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 2006: 130: 341-348. (Pubitemid 43202034)
25. Miura M, Satoh S, Inoue K, et al., Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. Steroids 2008: 73: 1052-1059.
26. Fanta S, Niemi M, Jönsson S, et al., Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics 2008: 18: 77-90.
27. Blumberg B, Sabbagh W, Juguilon H, et al., SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 1998: 12: 3195-3205. (Pubitemid 28496264)
28. Fanta S, Jönsson S, Karlsson MO, et al., Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: Evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism. J Clin Pharmacol 2010: 50: 581-597.
29. Press RR, De Fijter JW, Guchelaar HJ,. Individualizing calcineurin inhibitor therapy in renal transplantation-current limitations and perspectives. Curr Pharm Des 2010: 16: 176-186.
30. Press RR, Ploeger BA, Den Hartigh J, et al., Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit 2009: 31: 187-197.
31. Yu S, Wu L, Jin J, et al., Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation 2006: 81: 46-51. (Pubitemid 43122147)
32. Uesugi M, Masuda S, Katsura T, Oike F, Takada Y, Inui K,. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics 2006: 16: 119-127. (Pubitemid 43145680)
33. Hauser IA, Schaeffeler E, Gauer S, et al., ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005: 16: 1501-1511. (Pubitemid 41716536)